ArticleJournal of clinical pharmacology2008
Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization.
Article in Journal of clinical pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 55 citations in OpenAlex.
- Pilot Study of Model-Based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection.Antimicrobial agents and chemotherapy · 2018Trial
- Achieving target voriconazole concentrations more accurately in children and adolescents.Antimicrobial agents and chemotherapy · 2015Trial
- Building a Beta-Lactam Model-Informed Precision Dosing Service in a Quaternary Care Children's Hospital.Clinical and translational science · 2025Review
- Volumetric Absorptive Microsampling Combined with Mass Spectrometry to Support Pharmacokinetically-Guided Precision Dosing of Mycophenolate Mofetil in Pediatric Lupus Nephritis Patients.The journal of applied laboratory medicine · 2025Article
- Training the next generation of pharmacometric modelers: a multisector perspective.Journal of pharmacokinetics and pharmacodynamics · 2024Article
- The Significance of Bayesian Pharmacokinetics in Dosing for Critically Ill Patients: A Primer for Clinicians Using Vancomycin as an Example.Antibiotics (Basel, Switzerland) · 2023Review
- Effects of obesity on the pharmacology of proton pump inhibitors: current understanding and future implications for patient care and research.Expert opinion on drug metabolism & toxicology · 2023Review
- Implementation of Model-Based Dose Adjustment of Tobramycin in Adult Patients with Cystic Fibrosis.Pharmaceutics · 2022Article
- Dosage Individualization of Linezolid: Precision Dosing of Linezolid To Optimize Efficacy and Minimize Toxicity.Antimicrobial agents and chemotherapy · 2021Article
- Clinical pharmacology applications in clinical drug development and clinical care: A focus on Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Review
- Optimising antimicrobial therapy through the use of Bayesian dosing programs.International journal of clinical pharmacy · 2019Review
- Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients.Clinical pharmacokinetics · 2018Article
- A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.Clinical pharmacokinetics · 2017Article
- Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software.Therapeutic drug monitoring · 2016Article
- Design and Testing of an EHR-Integrated, Busulfan Pharmacokinetic Decision Support Tool for the Point-of-Care Clinician.Frontiers in pharmacology · 2016Article
- Pharmacokinetic modeling of therapies for systemic lupus erythematosus.Expert review of clinical pharmacology · 2015Review
- Paediatric models in motion: requirements for model-based decision support at the bedside.British journal of clinical pharmacology · 2015Review
- Are vancomycin trough concentrations adequate for optimal dosing?Antimicrobial agents and chemotherapy · 2014Article
- Population pharmacokinetics of abacavir in infants, toddlers and children.British journal of clinical pharmacology · 2013Article
- Benchmarking therapeutic drug monitoring software: a review of available computer tools.Clinical pharmacokinetics · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Individualized, model-based, target-oriented optimal concentration-controlled dosing of HIV medications can be beneficial to patients for whom there are limited dosing guidelines, such as children, adolescents, or patients with altered physiologic function. Barriers to this approach include lack of training, expertise, and access to appropriate software to assist the clinician. The authors present 4 illustrative clinical cases of HIV-infected patients whose therapy was optimized using population pharmacokinetic models (here generated from published studies) and supplemented by individualized Bayesian adaptive control of dosage regimens as implemented in the MM-USCPACK software. These 4 cases illustrate how clinicians can maximize therapeutic success in (1) patients with reduced drug clearance, (2) young adolescents transitioning to adult physiology, (3) patients with dose-dependent toxicity, and (4) adolescents with limited therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.